Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [3] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [3] Product Development - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and uses a proprietary linker to deliver a novel PH1 payload directly into tumors [3] - PH1 is a spliceosome inhibitor designed to disrupt RNA splicing within cancer cells, leading to cancer cell death and activation of immune cells [3] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, and it shows potential synergy with checkpoint inhibitors [3] Leadership Announcement - The company announced the appointment of Mark F. Kubik as the Head of Business Development – Oncology, along with the release of a "Meet the Team" video [2]
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology